1). 28.7% of the breast cancers were Her2-positive, which is consistent with literature reports ([22-24]), and amongst the samples that were Her2-positive in our cohort, 62.5% were also Pin1+. In summary, a majority of breast cancers overexpressed Pin1 (54%), and Pin1 overexpression was more prevalent in Her2-overexpressing tumors (62.5%) than in Her2-negative breast cancers. (Tab. 1). This evidence concerns the gene ERBB2 and breast cancer.